Shopping Cart
- Remove All
Your shopping cart is currently empty
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .
Catalog No. T7676
Select Batch
Purity:≥98%
Contact us for more batch information
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA
Catalog No. T7676
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $45 | In Stock | |
| 2 mg | $62 | In Stock | |
| 5 mg | $86 | In Stock | |
| 10 mg | $135 | In Stock | |
| 25 mg | $248 | In Stock | |
| 50 mg | $381 | In Stock | |
| 100 mg | $587 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $148 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "LSKL, Inhibitor of Thrombospondin TSP-1 2TFA"
Pirfenidone
Cited
T238653179-13-8
Pirfenidone (AMR69) inhibits the production of CCL2 and CCL12 in fibroblasts and also decreases TGF-β2 protein levels. Pirfenidone is an antifibrotic agent that is commonly used in studies related to pulmonary fibrosis and also has anti-inflammatory activity.
- $30
Size
QTY
CitedA 83-01 Cited
T3031909910-43-6
A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.
- $52
Size
QTY
CitedGalunisertib Cited
T2510700874-72-2
Galunisertib (LY2157299) is a TGF-β receptor type I (TGF-βRI) inhibitor (IC50=56 nM) that is selective. Galunisertib has antitumor activity and can be used in combination with PD-1 inhibitors.
- $40
Size
QTY
CitedAlantolactone Cited
T2896546-43-0
Alantolactone (Inula camphor)(Alant camphor), a sesquiterpene lactone, has potential activity against triple-negative breast Y MDA-MB-231 cells by suppressing the signal transducer and activator of transcription 3 (STAT3) signaling pathway.
- $50
Size
QTY
CitedMonocrotaline Cited
T2803315-22-0
Monocrotaline (Crotaline) is a pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes is noted after oral magnesium treatment.
- $41
Size
QTY
CitedChromenone 1
T613011639929-29-5In house
Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP). Chromenone 1 induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs.
- $117
Size
QTY
SB-431542 Cited
T1726301836-41-9
SB-431542 is an inhibitor of ALK5/TGF-β type I Receptor (IC50=94 nM) and is selective. SB 431542 also has inhibitory activity against ALK4 and ALK7 but not other proteins. SB 431542 can be used for induced differentiation of stem cells.
- $50
Size
QTY
CitedDMH-1 Cited
T19421206711-16-1
DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.
- $53
Size
QTY
CitedRepSox Cited
T6337446859-33-2
RepSox (ALK5 Inhibitor II) is a TGFβR-1/ALK5 inhibitor that selectively inhibits the binding of ATP to ALK5 and the autophosphorylation of ALK5 (IC50=23/4 nM). RepSox induces adipogenesis in MEFs cells.
- $30
Size
QTY
CitedBMP signaling agonist sb4 Cited
T7799100874-08-6
BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)
- $39
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β . |
| In vivo | Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy |
| Animal Research | Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy. |
| Alias | LSKL, Inhibitor of Thrombospondin TSP-1 |
| Molecular Weight | 686.64 |
| Formula | C25H44F6N6O9 |
| Cas No. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (40.05 mM)  | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | purchase LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA cost | order LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA chemical structure | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA in vivo | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA formula | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.